Hemolytic disease of the newborn (anti-Kell): Difference between revisions
No edit summary |
No edit summary |
||
| (4 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{DiseaseDisorder infobox | | {{DiseaseDisorder infobox | | ||
Name = HDN due to anti-Kell alloimmunization| | Name = HDN due to anti-Kell alloimmunization| | ||
| Line 5: | Line 6: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
{{SK}} Anti-Kell<sub>1</sub> | |||
==Overview== | ==Overview== | ||
'''Hemolytic disease of the newborn | '''Hemolytic disease of the newborn''' is the second most common cause of severe hemolytic diseases of newborns ([[HDN]]) after [[Rh disease]]. Anti-Kell<sub>1</sub> is becoming relatively more important as prevention of Rh disease is becoming more and more effective. | ||
==Pathophysiology== | |||
Hemolytic disease of the newborn (anti-Kell<sub>1</sub > is caused by a mis-match between the [[Kell antigen system|Kell antigens]] of the mother and fetus. About 91% of the population are Kell<sub>1</sub> negative and about 9% are Kell<sub>1</sub> positive. A fraction of a percentage are [[homozygous]] for Kell <sub>1</sub>. Therefore, about 4.5% of babies of a Kell<sub>1</sub> negative mother are Kell<sub>1</sub> positive. | Hemolytic disease of the newborn (anti-Kell<sub>1</sub > is caused by a mis-match between the [[Kell antigen system|Kell antigens]] of the mother and fetus. About 91% of the population are Kell<sub>1</sub> negative and about 9% are Kell<sub>1</sub> positive. A fraction of a percentage are [[homozygous]] for Kell <sub>1</sub>. Therefore, about 4.5% of babies of a Kell<sub>1</sub> negative mother are Kell<sub>1</sub> positive. | ||
The disease results when maternal [[antibodies]] to Kell<sub>1</sub> are transferred to the fetus across the [[placenta|placental barrier]]. These antibodies can cause severe [[anemia]] by interfering with the early proliferation of [[red blood cells]] as well as causing [[alloimmune]] hemolysis. Very severe disease can occur as early as 20 weeks gestation. [[Hydrops fetalis]] can also occur early. The finding of anti-Kell antibodies in an antenatal screening blood test ([[coombs test#indirect coombs test|indirect Coombs test]]) is an indication for early referral to a specialist service for assessment, management and treatment. | The disease results when maternal [[antibodies]] to Kell<sub>1</sub> are transferred to the fetus across the [[placenta|placental barrier]]. These antibodies can cause severe [[anemia]] by interfering with the early proliferation of [[red blood cells]] as well as causing [[alloimmune]] hemolysis. Very severe disease can occur as early as 20 weeks gestation. [[Hydrops fetalis]] can also occur early. The finding of anti-Kell antibodies in an antenatal screening blood test ([[coombs test#indirect coombs test|indirect Coombs test]]) is an indication for early referral to a specialist service for assessment, management and treatment. | ||
== | ===Anti-Kell<sub>2</sub>, anti-Kell<sub>3</sub> and anti-Kell<sub>4</sub> antibodies=== | ||
Hemolytic disease of the newborn can also be caused by anti-Kell<sub>2</sub>, anti-Kell<sub>3</sub> and anti-Kell<sub>4</sub> IgG antibodies. These are rarer and generally the disease is milder. | |||
==Causes== | |||
Mothers who are negative for the Kell<sub>1</sub> antigen develop antibodies after being exposed to red blood cells that are positive for Kell<sub>1</sub>. Over half of the cases of hemolytic disease of the newborn owing the anti-Kell antibodies are caused by multiple blood transfusions, with the remainder due to a previous pregnancy with a Kell<sub>1</sub> positive baby. | |||
== | ==Medical Therapy== | ||
It can be detected by routine antenatal antibody screening blood tests ([[coombs test#indirect coombs test|indirect Coombs test]]) in a similar way to [[Rh disease]]. The treatment of hemolytic disease of the newborn (anti-Rhc) is similar to the management of [[Rh disease]]. | It can be detected by routine antenatal antibody screening blood tests ([[coombs test#indirect coombs test|indirect Coombs test]]) in a similar way to [[Rh disease]]. The treatment of hemolytic disease of the newborn (anti-Rhc) is similar to the management of [[Rh disease]]. | ||
== | ==Primary Prevention== | ||
Suggestions have been made that women of child bearing age or young girls should not be given a [[Blood transfusion|transfusion]] with Kell<sub>1</sub> positive blood. Donated blood is not currently screened (in the U.S.A.) for the Kell blood group antigens as it is not considered cost effective at this time. | |||
It has been hypothesized that IgG anti-Kell<sub>1</sub> antibody injections would prevent sensitization to RBC surface Kell<sub>1</sub> antigens in a similar way that IgG anti-D antibodies ([[Rho(D) Immune Globulin]]) are used to prevent [[Rh disease]], but the methods for IgG anti-Kell<sub> 1</sub> antbodies have not been developed at the present time. | |||
==References== | ==References== | ||
{{Reflist|2}} | |||
==Related Chapters== | |||
== | |||
*[[Coombs test]] | *[[Coombs test]] | ||
*[[Hematology]] | *[[Hematology]] | ||
| Line 41: | Line 43: | ||
{{HDN}} | {{HDN}} | ||
{{ | |||
[[Category:Disease | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | |||
[[Category:Disease]] | |||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Obstetrics]] | [[Category:Obstetrics]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Transfusion medicine]] | [[Category:Transfusion medicine]] | ||
Latest revision as of 13:39, 21 September 2012
Template:DiseaseDisorder infobox
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Anti-Kell1
Overview
Hemolytic disease of the newborn is the second most common cause of severe hemolytic diseases of newborns (HDN) after Rh disease. Anti-Kell1 is becoming relatively more important as prevention of Rh disease is becoming more and more effective.
Pathophysiology
Hemolytic disease of the newborn (anti-Kell1 is caused by a mis-match between the Kell antigens of the mother and fetus. About 91% of the population are Kell1 negative and about 9% are Kell1 positive. A fraction of a percentage are homozygous for Kell 1. Therefore, about 4.5% of babies of a Kell1 negative mother are Kell1 positive.
The disease results when maternal antibodies to Kell1 are transferred to the fetus across the placental barrier. These antibodies can cause severe anemia by interfering with the early proliferation of red blood cells as well as causing alloimmune hemolysis. Very severe disease can occur as early as 20 weeks gestation. Hydrops fetalis can also occur early. The finding of anti-Kell antibodies in an antenatal screening blood test (indirect Coombs test) is an indication for early referral to a specialist service for assessment, management and treatment.
Anti-Kell2, anti-Kell3 and anti-Kell4 antibodies
Hemolytic disease of the newborn can also be caused by anti-Kell2, anti-Kell3 and anti-Kell4 IgG antibodies. These are rarer and generally the disease is milder.
Causes
Mothers who are negative for the Kell1 antigen develop antibodies after being exposed to red blood cells that are positive for Kell1. Over half of the cases of hemolytic disease of the newborn owing the anti-Kell antibodies are caused by multiple blood transfusions, with the remainder due to a previous pregnancy with a Kell1 positive baby.
Medical Therapy
It can be detected by routine antenatal antibody screening blood tests (indirect Coombs test) in a similar way to Rh disease. The treatment of hemolytic disease of the newborn (anti-Rhc) is similar to the management of Rh disease.
Primary Prevention
Suggestions have been made that women of child bearing age or young girls should not be given a transfusion with Kell1 positive blood. Donated blood is not currently screened (in the U.S.A.) for the Kell blood group antigens as it is not considered cost effective at this time.
It has been hypothesized that IgG anti-Kell1 antibody injections would prevent sensitization to RBC surface Kell1 antigens in a similar way that IgG anti-D antibodies (Rho(D) Immune Globulin) are used to prevent Rh disease, but the methods for IgG anti-Kell 1 antbodies have not been developed at the present time.